[Insulin Therapy of Type 2 Diabetes Mellitus (Update 2019)]

The present article is a recommendation of the Austrian Diabetes Association for the practical use of insulin in type 2 diabetes, including the various insulin regimens.

References

Monami M, Marchionni N, Mannucci E . Long-acting insulin analogues versus NPH human insulin in type 2 diabetes: a meta-analysis. Diabetes Res Clin Pract. 2008; 81(2):184-9. DOI: 10.1016/j.diabres.2008.04.007. View

Patel A, MacMahon S, Chalmers J, Neal B, Billot L, Woodward M . Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008; 358(24):2560-72. DOI: 10.1056/NEJMoa0802987. View

Gerstein H, Miller M, Byington R, Goff Jr D, Thomas Bigger J, Buse J . Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008; 358(24):2545-59. PMC: 4551392. DOI: 10.1056/NEJMoa0802743. View

Holman R, Paul S, Bethel M, Matthews D, Neil H . 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008; 359(15):1577-89. DOI: 10.1056/NEJMoa0806470. View

Ismail-Beigi F, Moghissi E, Tiktin M, Hirsch I, Inzucchi S, Genuth S . Individualizing glycemic targets in type 2 diabetes mellitus: implications of recent clinical trials. Ann Intern Med. 2011; 154(8):554-9. DOI: 10.7326/0003-4819-154-8-201104190-00007. View

Herman W, Buse J, Arakaki R, Dungan K, Jiang H, Jacobson J . Concomitant oral antihyperglycemic agent use and associated treatment outcomes after initiation of insulin therapy. Endocr Pract. 2011; 17(4):563-7. DOI: 10.4158/EP10348.OR. View

Poon K, King A . Glargine and detemir: Safety and efficacy profiles of the long-acting basal insulin analogs. Drug Healthc Patient Saf. 2011; 2:213-23. PMC: 3108694. DOI: 10.2147/DHPS.S7301. View

Donner T, Munoz M . Update on insulin therapy for type 2 diabetes. J Clin Endocrinol Metab. 2012; 97(5):1405-13. PMC: 3791411. DOI: 10.1210/jc.2011-2202. View

Hemmingsen B, Christensen L, Wetterslev J, Vaag A, Gluud C, Lund S . Comparison of metformin and insulin versus insulin alone for type 2 diabetes: systematic review of randomised clinical trials with meta-analyses and trial sequential analyses. BMJ. 2012; 344:e1771. DOI: 10.1136/bmj.e1771. View

10.

Heller S, Buse J, Fisher M, Garg S, Marre M, Merker L . Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN Basal-Bolus Type 1): a phase 3, randomised, open-label, treat-to-target non-inferiority trial. Lancet. 2012; 379(9825):1489-97. DOI: 10.1016/S0140-6736(12)60204-9. View

11.

Garber A, King A, Del Prato S, Sreenan S, Balci M, Munoz-Torres M . Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 2 diabetes (BEGIN Basal-Bolus Type 2): a phase 3, randomised, open-label, treat-to-target non-inferiority trial. Lancet. 2012; 379(9825):1498-507. DOI: 10.1016/S0140-6736(12)60205-0. View

12.

Robinson J, Neumiller J, Campbell R . Can a new ultra-long-acting insulin analogue improve patient care? Investigating the potential role of insulin degludec. Drugs. 2012; 72(18):2319-25. DOI: 10.2165/11642240-000000000-00000. View

13.

Wilding J, Woo V, Rohwedder K, Sugg J, Parikh S . Dapagliflozin in patients with type 2 diabetes receiving high doses of insulin: efficacy and safety over 2 years. Diabetes Obes Metab. 2013; 16(2):124-36. DOI: 10.1111/dom.12187. View

14.

Fulcher G, Christiansen J, Bantwal G, Polaszewska-Muszynska M, Mersebach H, Andersen T . Comparison of insulin degludec/insulin aspart and biphasic insulin aspart 30 in uncontrolled, insulin-treated type 2 diabetes: a phase 3a, randomized, treat-to-target trial. Diabetes Care. 2014; 37(8):2084-90. DOI: 10.2337/dc13-2908. View

15.

Roumie C, Greevy R, Grijalva C, Hung A, Liu X, Murff H . Association between intensification of metformin treatment with insulin vs sulfonylureas and cardiovascular events and all-cause mortality among patients with diabetes. JAMA. 2014; 311(22):2288-96. PMC: 4149288. DOI: 10.1001/jama.2014.4312. View

16.

Digenio A, Karve S, Candrilli S, Dalal M . Prandial insulin versus glucagon-like peptide-1 added to basal insulin: comparative effectiveness in the community practice setting. Postgrad Med. 2014; 126(6):49-59. DOI: 10.3810/pgm.2014.10.2820. View

17.

Scheen A . Pharmacodynamics, efficacy and safety of sodium-glucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus. Drugs. 2014; 75(1):33-59. DOI: 10.1007/s40265-014-0337-y. View

18.

Inzucchi S, Bergenstal R, Buse J, Diamant M, Ferrannini E, Nauck M . Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centred approach. Update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia. 2015; 58(3):429-42. DOI: 10.1007/s00125-014-3460-0. View

19.

Rhinehart A . Adding GLP-1 Receptor Agonist Therapy to Basal Insulin for Postprandial Glucose Control. Clin Diabetes. 2015; 33(2):73-5. PMC: 4398015. DOI: 10.2337/diaclin.33.2.73. View

20.

Ritzel R, Roussel R, Bolli G, Vinet L, Brulle-Wohlhueter C, Glezer S . Patient-level meta-analysis of the EDITION 1, 2 and 3 studies: glycaemic control and hypoglycaemia with new insulin glargine 300 U/ml versus glargine 100 U/ml in people with type 2 diabetes. Diabetes Obes Metab. 2015; 17(9):859-67. PMC: 4676914. DOI: 10.1111/dom.12485. View